RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Ceapro % Ownershipjust to add Westcoast's reply,
here is how the cash position has looked over the past few quarters with the most recent (ending Sept. 30) on the left, so we are comfortable to wait for news
end cash position $M | 6118.40 | 4267.32 | 2254.99 | 1857.20 | 2595.80 |
COVID has delayed some R&D expenses and with YTD rev up 35%, the cash position has moved up for the first time in years...
personally I'm hoping to see the following;
EOY - an out licensing deal and update on COVID study results / ability to produce commerical quantities of Y-BG for clinical studies
early Q1 2021 - completed installation of PGX equipment in Edmonton, timeline for PGX commercial equipment offshore
mid 2021 - results of BG pill